Nature Medicine, Published online: 06 January 2025; doi:10.1038/s41591-024-03360-5In a multicenter, open-label, randomized phase 2 trial, neoadjuvant chemoradiation with PD-1 blockade
Scientists behind the Oxford/AstraZeneca Covid jab are developing a vaccine for the bubonic plague amid growing concerns about the emergence
LANCASTER, S.C., Jan. 6, 2025 /PRNewswire/ -- Exciting changes are on the horizon for 'A Different Way to CE'! Since
BOSTON, Jan. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at
HOUSTON, Jan. 6, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare
SHANGHAI, Jan. 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative
SUWON, Corée du Sud, 6 janvier 2025 /PRNewswire/ -- Park Systems Corp. a annoncé aujourd'hui l'acquisition de Lyncée Tec SA,
The company is celebrating a decade of clean energy transformation in India with a 2.3 GW portfolio, 1.1 GW of
